Nano vs micro hydroxyapatite: what the label means

“Nano” on a toothpaste tube is a legal classification, not a performance claim. It means the particles meet a definition written into EU cosmetics law, which triggers a labelling requirement and a separate safety assessment. It does not mean the paste works better, and the human trials behind hydroxyapatite toothpaste mostly did not use the nano form at all.

That last sentence is the one worth sitting with, because the marketing runs the other way round.

What “nano” legally means

Article 2(1)(k) of the EU Cosmetics Regulation defines a nanomaterial as “an insoluble or biopersistent and intentionally manufactured material, with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm”.

Three things follow from the wording, and all three matter.

• It is about any one dimension, not the largest. A rod 122 nm long and 41 nm wide is a nanomaterial, because its width falls inside the range. Fig. 1 draws that to scale, and it is exactly the particle the EU’s safety committee assessed.
• It only covers material that is deliberately made that way and is insoluble or biopersistent. Nano-scale fragments that turn up incidentally are outside it.
• It triggers labelling. Article 19 requires that “all ingredients present in the form of nanomaterials shall be clearly indicated in the list of ingredients” and that “the names of such ingredients shall be followed by the word ‘nano’ in brackets”. That is why European tubes say Hydroxyapatite (nano) and American ones usually just say hydroxyapatite or, in the marketing copy, nano-hydroxyapatite.

“Micro” has no equivalent legal definition in cosmetics. It is a description: particles measured in micrometres rather than nanometres. A micrometre is a thousand nanometres, so a 2 µm particle is roughly fifty times the width of the nano rod in Fig. 1.

Which form the trials actually used

Here is the part the marketing skips. The clinical evidence for hydroxyapatite preventing caries rests on a small number of human trials, and when you read their titles and methods sections rather than the summaries about them:

Two of the four say microcrystalline in the title. The other two do not specify. None of them is a trial of nano-hydroxyapatite toothpaste for caries prevention.

Meanwhile the consumer category, particularly in the United States, is sold almost entirely on the word nano. That is a mismatch between what was tested and what is being marketed, and it is not a small one.

Is nano actually better?

The theoretical argument is reasonable. Enamel is built from apatite crystallites at the nanometre scale, and a smaller particle can in principle sit inside a surface defect that a larger one bridges over. Laboratory work does show particle size affecting how mineral deposits behave.

What does not exist, as far as we could find, is a human trial comparing nano and micro hydroxyapatite toothpaste head to head for caries or remineralisation. Searching the literature for one returns work on bone scaffolds, dental composites, glass ionomer cements and in-vitro biofilm models — useful materials science, none of it an answer to “which tube should I buy”.

So the honest state of play is: the theory favours nano, the human trials were mostly run on micro, and nobody has compared them in a mouth over a meaningful period. Anyone who tells you nano is clinically superior is extrapolating from bench work, which is the same move we spend most of this site pointing out — see what the flossing evidence actually measured for the general version.

Where the size argument came from

The pitch is called biomimetic, and it is a good pitch. Enamel is not a solid block of mineral; it is built from apatite crystallites packed into rods, and the damage that early decay does is a loss of mineral from between and within those structures rather than a hole you could see. A repair material that arrives at roughly the scale of the thing it is repairing is an appealing idea, and it is the reason hydroxyapatite got taken seriously at all rather than being dismissed as chalk.

The step that does not follow is from “plausible at that scale” to “better in a mouth”. Toothpaste is used for two minutes and then spat out; what matters is how much mineral ends up adhering and staying, in the presence of saliva, plaque and whatever the person last ate. That is an in-vivo question, and the size argument is an in-vitro one. It is exactly the gap between a mechanism and an outcome that the supplement-reference check is built to find, and it turns up here for the same reason it turns up everywhere: the mechanism is cheap to demonstrate and the outcome is expensive.

It is also worth noticing what the size claim quietly does for a seller. “Nano” sounds advanced and sounds specific, and it commits the manufacturer to nothing about how much hydroxyapatite is in the tube — which is the number that actually varied between the trials and the products.

What the regulators did about the nano form

Because nano triggers extra scrutiny, hydroxyapatite has a regulatory history that the micro form does not.

1. March 2023 — a restrictive opinion The EU’s Scientific Committee on Consumer Safety assessed hydroxyapatite (nano) and set low ceilings, subsequently written into Regulation (EU) 2024/858.
2. Industry submitted more data Manufacturers came back with evidence supporting higher concentrations in oral products.
3. June 2025 — the ceiling went up The committee concluded that hydroxyapatite (nano) is safe “at concentrations up to 29.5% in toothpaste, and up to 10% in mouthwash”. The regulator became more permissive, not less — which is the opposite of how the nano story is usually told.

That verdict comes with a specification almost nobody repeats: rod-shaped particles, at least 87% by number with an aspect ratio of 3 or less and the rest no more than 9, uncoated and not surface-modified, with a maximum length of 122 ± 43 nm. And a flat exclusion: “This Opinion is not applicable to any hydroxyapatite (nano) material that is composed of or contains needle-shaped particles.”

None of that is on a label. We go through what it does and does not license on is hydroxyapatite toothpaste safe to swallow.

How to read a label

• “Hydroxyapatite (nano)” on a European product is a legal declaration and tells you the particles meet the 1–100 nm definition. It is information, not a warning.
• Plain “hydroxyapatite” on a European product implies the manufacturer does not consider it a nanomaterial — in practice, a micro or microcluster form.
• On an American product, the ingredient list tells you nothing about size, because there is no equivalent labelling rule. “Nano-hydroxyapatite” in the marketing copy is a claim by the seller, not a regulated declaration.
• The concentration is the number that would actually be useful, and it is almost never disclosed. The trials used 10%. See what the brands actually disclose.

What this does not change

None of the above makes hydroxyapatite toothpaste a bad product. The evidence that it does something is real, if smaller and younger than its marketing implies, and we go through it in detail on does hydroxyapatite toothpaste actually work. The point of this page is narrower: the word on the front of the box is a regulatory category, and treating it as a quality grade is a mistake the category encourages.

When to ask a dentist

• You are switching away from fluoride and have had fillings in the last few years.
• You have visible white spots after orthodontic treatment — the population one of these trials was run in, and worth a proper look.
• You are choosing for a child. The concentration and the amount matter more than the particle size; see hydroxyapatite vs fluoride for children.

Fig. 1 is free to reuse under CC BY 4.0, like everything on the diagrams page.

References

1. European Union. Regulation (EC) No 1223/2009 on cosmetic products, Art. 2(1)(k) and Art. 19(1)(g). Official page, accessed 15 Sep 2026.
2. Scientific Committee on Consumer Safety. Opinion on hydroxyapatite (nano), submission IV, SCCS/1677/25 (preliminary 3 April 2025; final 2025). Official page, accessed 15 Sep 2026. · Funding: see ledger
3. Schlagenhauf U, Kunzelmann KH, Hannig C, et al. Impact of a non-fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries-susceptible orthodontic patients: a randomized, controlled 6-month trial. J Investig Clin Dent 2019;10(2):e12399. DOI · PubMed · Funding: see ledger
4. Paszynska E, Pawinska M, Gawriolek M, et al. Impact of a toothpaste with microcrystalline hydroxyapatite on the occurrence of early childhood caries: a 1-year randomized clinical trial. Sci Rep 2021;11:2650. DOI · PubMed · Funding: see ledger
5. Paszynska E, Pawinska M, Enax J, et al. Caries-preventing effect of a hydroxyapatite-toothpaste in adults: a 18-month double-blinded randomized clinical trial. Front Public Health 2023;11:1199728. DOI · PubMed · Funding: see ledger